GOODMAN AND GILMAN'S THE
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Question 1
Reference
Ch. 1 — Ethnopharmacology → Lead Identification from Natural
Products
Stem
A translational team is evaluating an alkaloid isolated from a
medicinal plant historically used for dysentery. In preclinical
,studies the compound shows micromolar inhibition of a
bacterial toxin in vitro but poor oral bioavailability in rats due to
first-pass hepatic metabolism. A 68-year-old patient with
cirrhosis is proposed for early human microdosing studies.
Which strategy best advances this compound toward a clinical
candidate while addressing the hepatic impairment concern?
Options
A. Use prodrug design to improve oral bioavailability and
conduct thorough hepatic clearance modeling before human
dosing.
B. Move directly to oral phase I trials at microdose levels
because low systemic exposure limits hepatic risk.
C. Prioritize structure–activity relationship (SAR) efforts to
increase potency only, ignoring metabolic liability until later.
D. Abandon the natural lead and switch to high-throughput
screening (HTS) for synthetic hits.
Correct Answer
A
Rationale — Correct
Prodrug design can mask metabolic hotspots to improve oral
bioavailability while in vitro/in vivo hepatic clearance modeling
(and simulation) helps predict exposure in cirrhotic patients;
this addresses both pharmacokinetics and safety before human
dosing. Prodrugs are a standard translational tactic when first-
pass metabolism limits exposure.
,Rationale — Incorrect
B: Microdosing avoids therapeutic exposure but doesn’t
evaluate metabolism or safety in hepatic impairment, risking
misleading PK and safety data.
C: Increasing potency without addressing high clearance may
still yield inadequate systemic exposure and fail in vivo.
D: Abandoning an active natural lead ignores translational value
and may be unnecessary; HTS is an alternative but not the best
immediate step.
Teaching Point
Prodrugs + hepatic clearance modeling mitigate first-pass
metabolism risks in lead development.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Question 2
Reference
Ch. 1 — High-Throughput Screening (HTS) → Hit Validation
Stem
A biotech uses fluorescence-based HTS to identify inhibitors of
a kinase implicated in pulmonary fibrosis. One hit reduces
fluorescence signal by 60% in the assay. In counterscreens the
compound quenches fluorescent dyes. A 55-year-old patient
sample shows high target expression. What is the most
, appropriate next experimental step before investing in lead
optimization?
Options
A. Run an orthogonal, label-free biochemical assay (e.g., mass
spectrometry or thermal shift) to confirm true target inhibition.
B. Proceed to medicinal chemistry optimization to improve
potency, assuming the HTS hit is genuine.
C. Test the compound in patient-derived cells immediately to
confirm biological activity.
D. Increase assay stringency in the same fluorescence HTS to
reduce false positives.
Correct Answer
A
Rationale — Correct
Orthogonal, label-free assays confirm target engagement
independent of fluorescence and eliminate artifacts caused by
dye quenching; validating hits before optimization prevents
wasting resources on false positives.
Rationale — Incorrect
B: Optimizing a false positive wastes resources.
C: Patient-derived cell testing is valuable but should follow
biochemical confirmation of target engagement to interpret
cellular effects correctly.
D: Increasing stringency in the same fluorescence assay may still
fail to detect quenching artifacts; orthogonal methods are
necessary.
PHARMACOLOGICAL BASIS OF
THERAPEUTICS
14TH EDITION
• AUTHOR(S)LAURENCE BRUNTON;
BJORN KNOLLMANN
TEST BANK
Ch. 1 — Drug Discovery: From Medicinal Plants to Computer-
Aided Drug Design
Question 1
Reference
Ch. 1 — Ethnopharmacology → Lead Identification from Natural
Products
Stem
A translational team is evaluating an alkaloid isolated from a
medicinal plant historically used for dysentery. In preclinical
,studies the compound shows micromolar inhibition of a
bacterial toxin in vitro but poor oral bioavailability in rats due to
first-pass hepatic metabolism. A 68-year-old patient with
cirrhosis is proposed for early human microdosing studies.
Which strategy best advances this compound toward a clinical
candidate while addressing the hepatic impairment concern?
Options
A. Use prodrug design to improve oral bioavailability and
conduct thorough hepatic clearance modeling before human
dosing.
B. Move directly to oral phase I trials at microdose levels
because low systemic exposure limits hepatic risk.
C. Prioritize structure–activity relationship (SAR) efforts to
increase potency only, ignoring metabolic liability until later.
D. Abandon the natural lead and switch to high-throughput
screening (HTS) for synthetic hits.
Correct Answer
A
Rationale — Correct
Prodrug design can mask metabolic hotspots to improve oral
bioavailability while in vitro/in vivo hepatic clearance modeling
(and simulation) helps predict exposure in cirrhotic patients;
this addresses both pharmacokinetics and safety before human
dosing. Prodrugs are a standard translational tactic when first-
pass metabolism limits exposure.
,Rationale — Incorrect
B: Microdosing avoids therapeutic exposure but doesn’t
evaluate metabolism or safety in hepatic impairment, risking
misleading PK and safety data.
C: Increasing potency without addressing high clearance may
still yield inadequate systemic exposure and fail in vivo.
D: Abandoning an active natural lead ignores translational value
and may be unnecessary; HTS is an alternative but not the best
immediate step.
Teaching Point
Prodrugs + hepatic clearance modeling mitigate first-pass
metabolism risks in lead development.
Citation
Brunton, L. L., & Knollmann, B. C. (2023). Goodman & Gilman’s
The Pharmacological Basis of Therapeutics (14th ed.). Ch. 1.
Question 2
Reference
Ch. 1 — High-Throughput Screening (HTS) → Hit Validation
Stem
A biotech uses fluorescence-based HTS to identify inhibitors of
a kinase implicated in pulmonary fibrosis. One hit reduces
fluorescence signal by 60% in the assay. In counterscreens the
compound quenches fluorescent dyes. A 55-year-old patient
sample shows high target expression. What is the most
, appropriate next experimental step before investing in lead
optimization?
Options
A. Run an orthogonal, label-free biochemical assay (e.g., mass
spectrometry or thermal shift) to confirm true target inhibition.
B. Proceed to medicinal chemistry optimization to improve
potency, assuming the HTS hit is genuine.
C. Test the compound in patient-derived cells immediately to
confirm biological activity.
D. Increase assay stringency in the same fluorescence HTS to
reduce false positives.
Correct Answer
A
Rationale — Correct
Orthogonal, label-free assays confirm target engagement
independent of fluorescence and eliminate artifacts caused by
dye quenching; validating hits before optimization prevents
wasting resources on false positives.
Rationale — Incorrect
B: Optimizing a false positive wastes resources.
C: Patient-derived cell testing is valuable but should follow
biochemical confirmation of target engagement to interpret
cellular effects correctly.
D: Increasing stringency in the same fluorescence assay may still
fail to detect quenching artifacts; orthogonal methods are
necessary.
